March 1, 2013
Angiotensin receptor blockers (ARBs) seem to have hit a plateau in the Japanese antihypertensive market, as sales of fixed-dose combination drugs containing mainstay ARBs failed to offset the sales slumps of their monodrugs in FY2012, ending the trend in recent...read more